通过全基因组整合性分析在支气管肺功能障碍症中发现了新的治疗标
Zhenyu Xiong1,2,3, Qingxiong Zhu1,2,3, Lei Hang4
1Department of Neonatology, Jiangxi Maternal and Child Health Hospital, Nanchang, China.
概括
这项研究确定了像CDH4和ENC1这样的关键基因,可以保护早产婴儿免受支气管肺功能障碍 (BPD) 的侵害. GRB10增加了BPD风险,表明了这种常见的婴儿呼吸道疾病的新治疗点.
科学领域:
- 基因组学就是基因组学.
- 新生儿科学 新生儿科学
- 呼吸系统医学 呼吸系统医学
背景情况:
- 支气管肺功能障碍 (BPD) 是极其早产婴儿中最常见的慢性呼吸道疾病.
- 了解BPD的遗传基础对于开发有效干预措施至关重要.
研究的目的:
- 在BPD中识别基因表达失调.
- 探索涉及到BPD病变的分子途径.
- 调查基因表达和BPD之间的因果关系.
主要方法:
- 将全基因组关联研究 (GWAS) 数据与单细胞转录组学 (scRNA-seq) 的整合.
- 应用孟德尔随机化 (MR) 分析来推断因果关系.
- 带受体相互作用分析和药物基因相互作用数据库 (DGIdb) 选.
主要成果:
- 肌纤维细胞被确定为BPD中高度互动的细胞类型.
- CDH4,ENC1和PAM被认为是保护性基因;GRB10与增加BPD风险有关.
- 免疫代谢途径与表皮细胞-介质细胞过渡相关,涉及PAM,GRB10和ENC1.1.
- 通过DGIdb.com识别的潜在治疗剂 (LM10,纳沃西莫德,齐普拉西)
结论:
- 综合基因组分析为BPD的遗传机制提供了新的见解.
- 已识别的基因和途径代表了BPD的潜在治疗点.
- 这些发现支持为患有BPD的新生儿制定个性化治疗策略.
相关概念视频
Pulmonary Hypertension: Classification and Pathogenesis
906
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
906
Cystic Fibrosis: Pathogenesis
1.1K
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
1.1K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
40
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
40


